Skye Bioscience, Inc. (SKYE)
NASDAQ · Manufacturing · Pharmaceutical preparations
SKYE price, last 12 months
Key stats
- Previous close
- $1.03
- Open
- $1.04
- Day range
- $0.7500 – $1.08
- 52-week range
- $0.4842 – $11.04
- Volume
- 168.4K
- Avg volume (20 days)
- 130.3K
- Market cap
- $4.8M
Performance
Technicals and fundamentals
About Skye Bioscience, Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $4.8M